Fascinating to see JAKi uptake in European JAK-pot centres - tofa was already on the decline pre-ORAL Surveillance - JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821